Price (delayed)
$1.57
Market cap
$12.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.97
Enterprise value
-$906,543
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path's lead
There are no recent dividends present for BPTH.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.